Nile Therapeutics, Inc.

Nile Therapeutics is a clinical-stage biopharmaceutical company developing innovative products for the treatment of cardiovascular disease and other areas of unmet medical need.

CD-NP is a novel rationally designed chimeric natriuretic peptide in clinical studies for an initial indication of acute decompensated heart failure. » More

2NTX-99 is a small molecule with anti-atherothrombotic and nitric oxide donating properties that is in pre-clinical development. » More

October 1, 2008 - Nile Therapeutics to Present at the Maxim Group Growth Conference » Read
August 27, 2008 - Nile Therapeutics to Present at BioCentury's NewsMakers in the Biotech Industry Conference » Read
August 14, 2008 - Nile Therapeutics, Inc. Reports 2008 Second Quarter Financial Results » Read


	Event:	Maxim Group Growth Conference
	Date:	October 7, 2008
	Time:	9:00am- 9:30am EDT
	Location:	Presentation: Morosco Room Breakout session: Plymouth Room Grand Hyatt Hotel, 109 East 42nd Street, New York, NY 10017
	Web Site:	http://www.wsw.com/webcast/maxim/nilt.ob


	Event:	Rodman and Renshaw Annual Global Investment Conference
	Date:	November 10, 2008
	Time:	2:00 pm - 2:25pm EDT
	Location:	Presentation: Kennedy II (4th floor) The New York Palace Hotel, 455 Madison Avenue (at 50th St.), New York, NY 10022
	Web Site:	http://www.rodm.com/conferences?id=19


	Event:	Lazard Capital Markets 5th Annual Healthcare Conference
	Date:	November 19, 2008
	Time:	9:00 a.m. (Presentation,) 9:30 a.m. (Breakout Meeting)
	Location:	The St. Regis, 2 East 55th Street, New York, NY 10022
	Web Site:	TBA

Interested investors or potential investors may conveniently receive E-mail alert messages whenever certain new company information is posted to this site. To automatically receive Nile Therapeutics, Inc. e-mail alerts, enter your e-mail address and click on the Subscribe button.